Global Peptic Ulcer Drugs Market to Reach US$ 6.1 Billion by 2032, Impelled by Rising Prevalence of Peptic Ulcers

March 28, 2023 | Healthcare

According to the latest report by IMARC Group, titled "Peptic Ulcer Drugs Market by Product Type (Proton Pump Inhibitors, Potassium-Competitive Acid Blocker (P-CAB), Antacids, H2-Antagonists, Antibiotics, Ulcer protective), Ulcer Type (Gastric Ulcer, Duodenal Ulcer, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region 2024-2032," the global peptic ulcer drugs market size reached US$ 4.8 Billion in 2023. A peptic ulcer is an open sore that develops in the lining of the stomach that is caused due to inflammation, radiation therapy, frequent oral and injectable administration of aspirins, and anti-inflammatory drugs. It is associated with abdominal pain, discomfort, nausea, vomiting, weight loss, bloating, belching, and loss of appetite. It is diagnosed through a combination of medical history, physical examination, and diagnostic tests, such as endoscopy, blood and stool tests, and biopsy. It is treated using medications and drugs, such as antibiotics, proton pump inhibitors (PPI), H2 antagonists, antacids, potassium-competitive acid blockers (P-CAB), and ulcer protectives, which aid in reducing the body aches, minimizing acid secretion, and protecting the stomach from digestive juices.

Global Peptic Ulcer Drugs Market Trends:

The surging prevalence of peptic ulcers and the growing geriatric population that is susceptible to developing these medical disorders represent one of the major factors driving the demand for peptic ulcer drugs and treatment around the world. Moreover, the rising number of individuals suffering from obesity, unhealthy lifestyle habits, and increasing instances of stomach cancer are some of the other factors favoring the growth of the market. In addition, governments of numerous countries are initiating campaigns to spread awareness about the benefits of early diagnosis of the disease. This, coupled with the expanding number of clinical studies and trials to develop new treatments for peptic ulcers, is contributing to the market growth. Apart from this, the easy availability of various generic drugs for treating and preventing stomach and intestinal ulcers and gastroesophageal reflux disease (GERD) via offline and online retail channels is strengthening the growth of the market. Besides this, significant improvements in the healthcare infrastructure and diagnostic technologies are creating a positive outlook for the market. On account of the aforementioned factors, the market is anticipated to reach a value of US$ 6.1 Billion by 2032, exhibiting a CAGR of 2.65% during 2024-2032.

Market Summary:

On the basis of the product type, the market has been segmented into proton pump inhibitors, potassium-competitive acid blocker (P-CAB), antacids, h2-antagonists, antibiotics, and ulcer protective. Presently, antibiotics holds the largest market share.
Based on the ulcer type, the market has been classified into gastric ulcer, duodenal ulcer, and others. Presently, duodenal ulcer represented the largest segment.
On the basis of the distribution channel, the market has been categorized into hospital, retail and online pharmacies. Hospital pharmacies currently accounted for the biggest market share.
Based on the region, the market has been divided into North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia and others); Europe (Germany, France, United Kingdom, Italy, Spain, Russia and others); Latin America (Brazil, Mexico and others); and the Middle East and Africa. Amongst these, North America (the United States and Canada) enjoys the leading position in the market.
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market. Some of the key players include Abbott Laboratories, AstraZeneca plc, Boehringer Ingelheim International GmbH, Novitium Pharma LLC, Pfizer Inc., PharmaKing Co. Ltd., RedHill Biopharma Ltd, Viatris Inc., Yuhan Corporation, and Zydus Lifesciences Limited.

Report Scope:

Report Features	Details
Base Year of the Analysis	2023
Historical Period	2018-2023
Forecast Period	2024-2032
Units	US$ Billion
Segment Coverage	Product Type, Ulcer Type, Distribution Channel, Region
Region Covered	Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered	United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered	Abbott Laboratories, AstraZeneca plc, Boehringer Ingelheim International GmbH, Novitium Pharma LLC, Pfizer Inc., PharmaKing Co. Ltd., RedHill Biopharma Ltd, Viatris Inc., Yuhan Corporation, Zydus Lifesciences Limited, etc.
Customization Scope	10% Free Customization
Report Price and Purchase Option	Single User License: US$ 3899 Five User License: US$ 4899 Corporate License: US$ 5899
Post-Sale Analyst Support	10-12 Weeks
Delivery Format	PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group
30 N A
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800

Need more help?

Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.

Global Peptic Ulcer Drugs Market to Reach US$ 6.1 Billion by 2032, Impelled by Rising Prevalence of Peptic Ulcers

Purchase options

Single User License ~~$3899~~ $2999
Five User License ~~$4899~~ $3999
Corporate User License ~~$5899~~ $4999

Inquire Before Buying

Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Speak to an Analyst

Request Brochure

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.